Radioimmunotherapy with I-131-anti-B1 (anti CD20) antibody decreases spleen size in patients with non-Hodgkin's lymphoma

被引：0
|
作者：
Zasadny, KR
Gates, VL
Kaminski, MS
Wahl, RL
机构：
来源：
RADIOLOGY | 1998年 / 209P卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1007
引用
收藏
页码：367 / 368
页数：2
相关论文
共 50 条
  • [21] Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease
    Giles, FJ
    Vose, JM
    Do, KA
    Johnson, MM
    Manshouri, T
    Bociek, G
    Bierman, PJ
    O'Brien, SM
    Keating, MJ
    Kantarjian, HM
    Armitage, JO
    Albitar, M
    BRITISH JOURNAL OF HAEMATOLOGY, 2003, 123 (05) : 850 - 857
  • [22] Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma
    Gui, Lin
    Han, Xiaohong
    He, Xiaohui
    Song, Yuanyuan
    Yao, Jiarui
    Yang, Jianliang
    Liu, Peng
    Qin, Yan
    Zhang, Shuxiang
    Zhang, Weijing
    Gai, Wenlin
    Xie, Liangzhi
    Shi, Yuankai
    CHINESE JOURNAL OF CANCER RESEARCH, 2016, 28 (02) : 197 - 208
  • [23] Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma
    Lin Gui
    Xiaohong Han
    Xiaohui He
    Yuanyuan Song
    Jiarui Yao
    Jianliang Yang
    Peng Liu
    Yan Qin
    Shuxiang Zhang
    Weijing Zhang
    Wenlin Gai
    Liangzhi Xie
    Yuankai Shi
    Chinese Journal of Cancer Research, 2016, (02) : 197 - 208
  • [24] Pretargeted Versus Directly Targeted Radioimmunotherapy Combined with Anti-CD20 Antibody Consolidation Therapy of Non-Hodgkin Lymphoma
    Sharkey, Robert M.
    Karacay, Habibe
    Johnson, Christine R.
    Litwin, Samuel
    Rossi, Edmund A.
    McBride, Williarn J.
    Chang, Chien-Hsing
    Goldenbero, David M.
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50 (03) : 444 - 453
  • [25] Anti CD20 antibody (rituximab) therapy leads to high molecular remission rate with favourable outcome in patients with non-Hodgkin's lymphoma.
    Trneny, M
    Cerny, J
    Papajik, T
    Slavickova, A
    Prochazka, B
    Indrak, K
    Klener, P
    BLOOD, 2001, 98 (11) : 605A - 606A
  • [26] Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody
    Sharkey, Robert M.
    Karacay, Habibe
    Litwin, Samuel
    Rossi, Edmund A.
    McBride, William J.
    Chang, Chien-Hsing
    Goldenberg, David M.
    CANCER RESEARCH, 2008, 68 (13) : 5282 - 5290
  • [27] Dosimetry of I-131 anti-B1 (anti-CD20) antibody for non-Hodgkin's lymphoma: Comparison of up-front treatment vs. chemotherapy-refractory patients.
    Rommelfanger, SG
    Zasadny, KR
    Gates, VL
    Fisher, SJ
    Kaminski, MS
    Wahl, RL
    JOURNAL OF NUCLEAR MEDICINE, 1998, 39 (05) : 186P - 186P
  • [28] 131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma
    Gopal, Ajay K.
    Pagel, John M.
    Fromm, Jonathan R.
    Wilbur, Shani
    Press, Oliver W.
    BLOOD, 2009, 113 (23) : 5905 - 5910
  • [29] Radioimmunotherapy (RIT) for non-Hodgkin's lymphoma. Preliminary results using I-131 labelled anti-CD-20 antibody (Tositumomab) in 47 patients at two years post-therapy.
    Jan, H
    Britton, KE
    Davies, A
    Sobnack, R
    Foley, RR
    Barlow, R
    Mather, SJ
    Ellison, D
    Rohatiner, AZ
    Lister, TA
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (08): : 980 - 980
  • [30] Effect of anti lymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphocytes.
    Schillaci, O
    DeNardo, GL
    DeNardo, SJ
    Goldstein, DS
    Kroger, LA
    O'Donnell, RT
    Lamborn, KR
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 277P - 277P
12345